INSR and Insulin resistance: As depicted in Fig. 4, the specific serine protease inhibitor AEBSF attenuated systemic inflammation, obesity, and insulin resistance in diabetic mice, probably by modulating insulin receptor and cytokine expression in VAD tissue.